DrugPatentWatch Database Preview
Iloprost - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for iloprost and what is the scope of freedom to operate?
Iloprost
is the generic ingredient in one branded drug marketed by Actelion Pharms Ltd and is included in one NDA. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for iloprost. One supplier is listed for this compound.
Summary for iloprost
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 4 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 60 |
Clinical Trials: | 85 |
Patent Applications: | 4,799 |
Formulation / Manufacturing: | see details |
DailyMed Link: | iloprost at DailyMed |
Recent Clinical Trials for iloprost
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Innovation Fund Denmark | Phase 2/Phase 3 |
Jakob Stensballe, MD, PhD | Phase 2/Phase 3 |
Independent Research Fund Denmark | Phase 2/Phase 3 |
Pharmacology for iloprost
Drug Class | Prostacycline |
Medical Subject Heading (MeSH) Categories for iloprost
Synonyms for iloprost
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2) |
(16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2 |
(1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane |
(1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane |
(5E)-5-((3aS,4R,5R,6aS)-5-Hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid |
(5e)-5-[(3as,4r,5r,6as)-5-Hydroxy-4-[(1e,3s,4r)-3-Hydroxy-4-Methyloct-1-En-6-Yn-1-Yl]hexahydropentalen-2(1h)-Ylidene]pentanoic Acid |
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid |
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid |
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid |
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic Acid |
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid |
(5E)-5-[(3aS,5R,6aS)-4-[(E,3S)-4-methyl-3-oxidanyl-oct-1-en-6-ynyl]-5-oxidanyl-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid |
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid |
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid |
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid |
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid |
(E)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-ynyl)hexahydropentalen-2(1H)-ylidene)pentanoic acid |
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure |
(Z)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid |
[3H]-Iloprost |
1212AH |
16(R)-Iloprost |
5-((3aS,5R,6aS,E)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid |
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid |
5-[[(2E,3aS,4R,5R,6aS)-Octahydro-5-hydroxy-4-[(1E,3S,4R)-3-hydroxy-4-methyl-1-octene-6-ynyl]pentalene]-2-ylidene]pentanoic acid |
6,9.alpha.-Methylene-11.alpha.,15S-dihydroxy-16-methyl-prosta-5E,13E-dien-18-yn-1-oic acid |
73873-87-7 |
74843-13-3 |
78919-13-8 |
A839531 |
AC-6105 |
AC1NSK5T |
AC1O5JP3 |
AC1Q1J28 |
AHG2128QW6 |
AKOS024456922 |
AKOS025402197 |
AN-10394 |
AN-36592 |
B6933 |
BAY Q6256 |
BAY-q-6256 |
BC682483 |
BCP05834 |
BDBM23954 |
BRD-A45664787-001-01-4 |
BRD-A45664787-001-02-2 |
C22H32O4 |
CAS-78919-13-8 |
CHEBI:63916 |
CHEMBL494 |
Ciloprost |
CS-5586 |
CTK8G0274 |
D02721 |
DB01088 |
DSSTox_CID_21046 |
DSSTox_GSID_41046 |
DSSTox_RID_79616 |
DTXSID2041046 |
Endoprost |
GTPL1895 |
HIFJCPQKFCZDDL-ACWOEMLNSA-N |
HIFJCPQKFCZDDL-JYTNZNGZSA-N |
HMS2090A19 |
HMS3650E08 |
HY-A0096 |
IL2 |
Ilomedin |
Ilomedine |
Iloprost (USAN/INN) |
Iloprost [BAN:INN] |
Iloprost [USAN:INN:BAN] |
Iloprost R-isomer |
Iloprost, >=98% (HPLC) |
Iloprostum |
Iloprostum [Latin] |
J-502615 |
K395 |
KS-00001F60 |
LS-101845 |
MolPort-023-276-312 |
MolPort-039-138-876 |
NCGC00181784-01 |
PDSP2_001536 |
Pentanoic acid, 5-((3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-, (5E)- |
Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)- |
Pentanoic acid,5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]-,(5E)- |
RP17693 |
SCHEMBL13386495 |
SCHEMBL13386497 |
SCHEMBL4357 |
SCHEMBL532499 |
SCHEMBL6083382 |
SH-401 |
SR-01000946274 |
SR-01000946274-1 |
SR-05000001498 |
SR-05000001498-1 |
SR-05000001498-2 |
Tox21_113586 |
UNII-AHG2128QW6 |
UNII-JED5K35YGL component HIFJCPQKFCZDDL-GBSCXWAGSA-N |
Ventavis |
Ventavis (TN) |
ZINC3784120 |
ZK 00036374 |
ZK 36374 |
ZK-00036374 |
ZK-36374 |
ZK-363775 |
US Patents and Regulatory Information for iloprost
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion Pharms Ltd | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-001 | Dec 29, 2004 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Actelion Pharms Ltd | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-003 | Aug 7, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
Actelion Pharms Ltd | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-002 | Dec 8, 2005 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.